Measuring patient life engagement in schizophrenia in clinical trials and clinical practice

Professor Andrea Fagiolini sat down with us at ECNP 2021 to discuss how patient life engagement in a person with schizophrenia is hard to measure in clinical practice as it’s not standardized; however, proxy measures include treatment satisfaction. Secondary outcome measures that capture patient life engagement could be added to clinical trials. It’s important to understand what a patient’s priorities are in terms of treatment satisfaction as individuals differ. Focusing on life engagement, though more time consuming up front, can lead to better long-term outcomes.

You are leaving Progress in Mind
Please confirm your email
We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.
The information on this site is exclusively intented for health care professionals.
All the information included in the Website is related to products of the local market and, therefore, directed to health professionals legally authorized to prescribe or dispense medications with professional practice. The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.
Register for access to Progress in Mind in your country